These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32730628)

  • 61. Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial.
    Fabris E; Van't Hof A; Hamm CW; Lapostolle F; Lassen JF; Goodman SG; Ten Berg JM; Bolognese L; Cequier A; Chettibi M; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Zeymer U; Cantor WJ; Kerneis M; Diallo A; Vicaut E; Montalescot G;
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):E369-E377. PubMed ID: 30302940
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.
    Yang A; Pon Q; Lavoie A; Crawford JJ; Harenberg S; Zimmermann RH; Booker J; Kelly S; Lavi S; Cantor WJ; Mehta SR; Bagai A; Goodman SG; Cheema AN; Dehghani P
    J Thromb Thrombolysis; 2018 Feb; 45(2):225-233. PubMed ID: 29170875
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of Ticagrelor on Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction (HEALING-AMI).
    Park Y; Koh JS; Lee JH; Park JH; Shin ES; Oh JH; Chun W; Lee SY; Bae JW; Kim JS; Kim W; Suh JW; Yang DH; Hong YJ; Chan MY; Kang MG; Park HW; Hwang SJ; Hwang JY; Ahn JH; Choi SW; Jeong YH;
    JACC Cardiovasc Interv; 2020 Oct; 13(19):2220-2234. PubMed ID: 33032710
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [The variation of serum uric acid levels among patients with myocardial infarction treated with ticagrelor and the association between serum uric acid and platelet reactivity].
    Song L; Xu DY; Zhou P; Liu C; Sheng ZX; Li JN; Zhou JY; Chen RZ; Chen Y; Zhao HJ; Yan HB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Feb; 49(2):170-175. PubMed ID: 33611904
    [No Abstract]   [Full Text] [Related]  

  • 65. Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Liu HL; Wei YJ; Jin ZG; Zhang J; Ding P; Yang SL; Luo JP; Ma DX; Liu Y; Han W
    Medicine (Baltimore); 2016 May; 95(22):e3756. PubMed ID: 27258504
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.
    Kubica J; Adamski P; Ostrowska M; Sikora J; Kubica JM; Sroka WD; Stankowska K; Buszko K; Navarese EP; Jilma B; Siller-Matula JM; Marszałł MP; Rość D; Koziński M
    Eur Heart J; 2016 Jan; 37(3):245-52. PubMed ID: 26491112
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study.
    Adamski P; Sikora J; Laskowska E; Buszko K; Ostrowska M; Umińska JM; Sikora A; Skibińska N; Sobczak P; Adamska U; Rość D; Kubica A; Paciorek P; Marszałł MP; Navarese EP; Gorog DA; Kubica J
    PLoS One; 2017; 12(10):e0186013. PubMed ID: 29023473
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The MOVEMENT Trial.
    Holm M; Tornvall P; Henareh L; Jensen U; Golster N; Alström P; Santos-Pardo I; Witt N; Fedchenko N; Venetsanos D; Beck O; van der Linden J
    J Am Heart Assoc; 2019 Jan; 8(2):e010152. PubMed ID: 30636504
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
    Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modified ticagrelor loading doses according to the vasodilator-stimulated phosphoprotein phosphorylation index improve the clinical outcome in ST-elevation myocardial infarction patients with high on-treatment platelet reactivity.
    Liu Y; Kang S; Li X; Liu Z; Gao Y; Wang X
    Cardiol J; 2023; 30(5):771-780. PubMed ID: 34581430
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
    Gill K; Servati N; Flahive J; Fraielli K
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):625-629. PubMed ID: 34236915
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of Preloading Strategy With Ticagrelor on Periprocedural Myocardial Injury in Patients With Non-ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy.
    Karaca OF; Cimci M; Raimoglou D; Durmaz E; Yalman H; Tekin AM; Incesu G; Ozkan FU; Yavuz B; Karadag B
    J Cardiovasc Pharmacol; 2024 Apr; 83(4):311-316. PubMed ID: 38241694
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
    Rollini F; Franchi F; Hu J; Kureti M; Aggarwal N; Durairaj A; Park Y; Seawell M; Cox-Alomar P; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    J Am Coll Cardiol; 2016 May; 67(17):1994-2004. PubMed ID: 27012781
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis.
    Bellemain-Appaix A; Bégué C; Bhatt DL; Ducci K; Harrington RA; Roe M; Wiviott SD; Cucherat M; Silvain J; Collet JP; Bernasconi F; Montalescot G
    EuroIntervention; 2018 May; 14(1):78-85. PubMed ID: 29469030
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
    Alexopoulos D; Kontoprias K; Gkizas V; Karanikas S; Ziakas A; Barampoutis N; Tsigkas G; Koutsogiannis N; Davlouros P; Patsilinakos S; Karvounis H; Hahalis G; Xanthopoulou I
    Platelets; 2016 Jul; 27(5):420-6. PubMed ID: 26763727
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 77. How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).
    Bergmeijer TO; Godschalk TC; Janssen PWA; Berge KVD; Breet NJ; Kelder JC; Hackeng CM; Ten Berg JM
    Semin Thromb Hemost; 2017 Jun; 43(4):439-446. PubMed ID: 28561235
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial.
    Gargiulo G; Esposito G; Cirillo P; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Avvedimento M; Tebaldi M; Wahl A; Hunziker L; Billinger M; Heg D; Windecker S; Valgimigli M
    J Cardiovasc Transl Res; 2021 Feb; 14(1):110-119. PubMed ID: 32096064
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
    Mshelbwala FS; Hugenberg DW; Kreutz RP
    J Thromb Thrombolysis; 2020 Oct; 50(3):619-627. PubMed ID: 32152791
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
    Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK
    BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.